Day One Biopharmaceuticals (NASDAQ:DAWN) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a research note released on Friday morning, Benzinga reports. HC Wainwright currently has a $40.00 price target on the stock.

A number of other research analysts have also commented on the company. Needham & Company LLC reissued a buy rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, June 19th. JPMorgan Chase & Co. increased their price objective on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an overweight rating in a report on Monday, April 22nd. Wedbush reissued an outperform rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. Finally, Piper Sandler reaffirmed an overweight rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, July 8th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Day One Biopharmaceuticals has an average rating of Moderate Buy and an average price target of $37.67.

Day One Biopharmaceuticals Price Performance

DAWN opened at $15.36 on Friday. Day One Biopharmaceuticals has a fifty-two week low of $9.67 and a fifty-two week high of $18.07. The business has a 50-day moving average of $14.00 and a 200-day moving average of $14.83. The company has a market capitalization of $1.34 billion, a PE ratio of -6.12 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Monday, May 6th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). On average, equities research analysts expect that Day One Biopharmaceuticals will post -2.69 earnings per share for the current fiscal year.

Insider Transactions at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 2,267 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $16.08, for a total transaction of $36,453.36. Following the sale, the insider now owns 1,171,081 shares of the company’s stock, valued at approximately $18,830,982.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Charles N. York II sold 2,675 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $16.08, for a total transaction of $43,014.00. Following the sale, the chief financial officer now owns 224,868 shares of the company’s stock, valued at approximately $3,615,877.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Samuel C. Blackman sold 2,267 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $16.08, for a total value of $36,453.36. Following the sale, the insider now directly owns 1,171,081 shares in the company, valued at approximately $18,830,982.48. The disclosure for this sale can be found here. In the last quarter, insiders have sold 195,534 shares of company stock valued at $3,367,830. 8.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of DAWN. Quest Partners LLC bought a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth approximately $29,000. Quintet Private Bank Europe S.A. raised its position in Day One Biopharmaceuticals by 43.2% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after purchasing an additional 1,000 shares during the last quarter. SG Americas Securities LLC bought a new position in Day One Biopharmaceuticals in the 2nd quarter valued at $113,000. China Universal Asset Management Co. Ltd. raised its position in Day One Biopharmaceuticals by 352.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,067 shares of the company’s stock valued at $147,000 after purchasing an additional 7,841 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in Day One Biopharmaceuticals in the 4th quarter valued at $156,000. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.